Amryt Pharma PLC (LON:AMYT) shares hit a new 52-week high on Tuesday . The company traded as high as GBX 160 ($1.97) and last traded at GBX 157.50 ($1.94), with a volume of 68756 shares changing hands. The stock had previously closed at GBX 154 ($1.90).
AMYT has been the topic of a number of analyst reports. Berenberg Bank reaffirmed a “house stock” rating on shares of Amryt Pharma in a report on Monday, May 18th. Shore Capital reaffirmed a “hold” rating on shares of Amryt Pharma in a report on Monday, May 11th.
The stock has a fifty day simple moving average of GBX 127.62 and a two-hundred day simple moving average of GBX 117.50. The company has a market cap of $245.65 million and a PE ratio of -1.84. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 180.25.
Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The company operates through two segments, Commercial and Research and Development. It offers Lojuxta (lomitapide), a drug used to treat a rare life-threatening disease Homozygous Familial Hypercholesterolaemia; and a range of dermo cosmetic products under the Imlan brand.
Featured Article: What is meant by a buy rating?
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.